A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Trial Profile

A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Suspended
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Palovarotene (Primary)
  • Indications Fibrodysplasia ossificans progressiva
  • Focus Adverse reactions
  • Sponsors Clementia Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2016 Status changed from recruiting to suspended.
    • 07 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 18 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top